AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23846820
Drug: Low‐dose spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐dose spironolactone (50 mg/d)
Trial: 20618506
Drug: Intravenous siplizumab
RxNorm normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous siplizumab (0.012 mg/kg and 0.04 mg/kg every 2 weeks for 8 doses)
Trial: 20618506
Drug: Subcutaneous siplizumab
RxNorm normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous siplizumab (5 mg x 12 weeks, 5 mg x 6 weeks + placebo x 6 weeks, 7 mg x 4 weeks + placebo x 8 weeks)
Trial: 12744899
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV) conjugated to outer membrane protein of Neisseria meningitidis serogroup b, administered at 2, 4, 6, and 12 months of age.
Trial: 12744899
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV) after the 12 month dose.
Trial: 10567989
Drug: Sterilized solution
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterilized solution (Rhinomer, Zyma SA, Nyon, France)
Trial: 9117049
Drug: Active antibiotic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antibiotic pastille
Trial: 22736123
Drug: Traditional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional fluid therapy
Trial: 28628684
Drug: Two treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatment sessions using BodyFX bipolar RF device
Trial: 28628684
Drug: Three treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three treatment sessions using BodyFX bipolar RF device
Trial: 28628684
Drug: Eight weekly
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight weekly sessions using BodyFX bipolar RF device
Trial: 9439085
Drug: Naratriptan 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan 0.1 mg
Trial: 9439085
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of Naratriptan
Trial: 8502260
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human growth hormone (Protropin)
Trial: 27388361
Drug: 0.5% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% chlorhexidine gluconate (CHG) in aqueous solution
Trial: 23873319
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 550 μg fluoride (F)/g, pH 4.5
Trial: 23873319
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 1,100 μg F/g, pH 7.0
Trial: 23873319
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: 550 μg F/g, pH 7.0
Trial: 20103775
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100,000 U of oral vitamin D2 at baseline and 10 weeks)
Trial: 18996875
Drug: Dual-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-fortified salt with iron as micronized ground ferric pyrophosphate (MGFePP) at 2 mg/g salt
Trial: 18996875
Drug: Dual-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-fortified salt with iron as encapsulated ferrous fumarate (EFF) at 2 mg/g salt
Trial: 9195022
Drug: Home-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physical therapy (number of visits determined by patient response)
Trial: 3011440
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg orally)
Trial: 29742942
Drug: Combined low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low dose vaginal misoprostol plus Foley catheter
Trial: 29240860
Drug: ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixekizumab 80 mg injection every 2 weeks after a 160 mg starting dose
Trial: 18763027
Drug: etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etanercept 50 mg twice weekly
Trial: 26348584
Drug: Low-dose aripiprazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aripiprazole added to antidepressant therapy
Trial: 26348584
Drug: Pooled response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pooled response rates across phases and treatments
Trial: 23557594
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal system (2-16 mg/24 h)
Trial: 18786961
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 30 microg adrenaline
Trial: 18786961
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (0.30 ml)
Trial: 11159240
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg hyperbaric lidocaine 5% (n = 100)
Trial: 11159240
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg hyperbaric bupivacaine 0.75% (n = 100)
Trial: 9628552
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake 300 to 700 mg/d
Trial: 9628552
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake >700 mg/d
Trial: 9628552
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake >300 mg/d from coffee (smoking women)
Trial: 9628552
Drug: Nonsmoking women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsmoking women with caffeine intake <300 mg/d
Trial: 3060967
Drug: Cefotetan 2
RxNorm normalized name: cefotetan 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan 2 g administered during induction of anesthesia
Trial: 31306889
Drug: Individualized disease-
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized disease- and treatment-related information
Trial: 19367181
Drug: Minimal enteral
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal enteral feeding (MEF) initiated 5 days after bowel reintegration, increased by 12 mL/kg/day
Trial: 14728005
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (loading dose of 300 mg followed by 75 mg daily)
Trial: 9517604
Drug: Intensive smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive smoking cessation program with inhaled bronchodilator
Trial: 8000984
Drug: Low-dose mitoxantrone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mitoxantrone (MX)
Trial: 3149291
Drug: atenolol, 50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol, 50-100 mg
Trial: 3149291
Drug: trichloromethiazide, 2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trichloromethiazide, 2-4 mg
Trial: 3149291
Drug: slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow release nifedipine, 40-80 mg
Trial: 3149291
Drug: captopril, 37.5-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril, 37.5-75 mg
Trial: 31583699
Drug: Melatonin 8
RxNorm normalized name: Calcium Carbonate/Melatonin 84 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 8 mg
Trial: 31583699
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of placebo to any dose of melatonin
Trial: 26921116
Drug: Individualized metacognitive
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized metacognitive therapy program (MCT+)
Trial: 21962194
Drug: Solvent controls
RxNorm normalized name: solvent yellow 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solvent controls (plain distilled water and water-ethanol (95%) solution)
Trial: 18923232
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine
Trial: 18923232
Drug: Antiangiotensin vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiotensin vaccine
Trial: 18923232
Drug: Anti-obesity vaccine
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-obesity vaccine
Trial: 18923232
Drug: Vaccine targeting
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine targeting heat shock proteins and oxidized low-density lipoprotein
Trial: 18923232
Drug: Vaccine to
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine to inhibit cholesteryl ester transfer protein
Trial: 17041286
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to antipsychotic medication
Trial: 17041286
Drug: Mediating variables
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediating variables (symptomatic impairment, global functioning, medication side effects)
Trial: 9542560
Drug: Deltoid injection
RxNorm normalized name: Ambrosia deltoidea pollen
DrugBank: Ambrosia deltoidea pollen (DB10765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltoid injection of scopolamine 6 micrograms/kg plus morphine 200 micrograms/kg
Trial: 9542560
Drug: Gluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluteal injection of scopolamine 6 micrograms/kg plus morphine 200 micrograms/kg
Trial: 8168033
Drug: Double beta‐lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double beta‐lactam combination (Group C)
Trial: 8168033
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy without additional antifungal therapy
Trial: 2462402
Drug: Alfuzosin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (7.5 mg or 10 mg/day)
Trial: 22965961
Drug: mFOLFOX6/cediranib 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6/cediranib 20 mg
Trial: 17325505
Drug: Remifentanil (0-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0-15 ng/ml) and inhaled sevoflurane (0-6 vol%)
Trial: 11472709
Drug: L-methionine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-methionine (100 mg/kg at -6 hours)
Trial: 9787721
Drug: Medication +
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication + diet
Trial: 7664725
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of aqueous retinyl palmitate oral solution
Trial: 773392
Drug: Quinidine polygalacturonate
RxNorm normalized name: QUINIDINE POLYGALACTURONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine polygalacturonate (short-acting), 4 daily doses
Trial: 773392
Drug: Quinidine arabogalactan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine arabogalactan sulphate (long-acting), 2 daily doses
Trial: 14700452
Drug: Paroxetine controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine controlled-release (CR)
Trial: 21895859
Drug: Paroxetine immediate-release
RxNorm normalized name: paroxetine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine immediate-release (IR)
Trial: 17895776
Drug: Right-arm injection
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right-arm injection of contrast material (80 mL, iodine concentration 300 mg/mL, 2 mL/s injection rate)
Trial: 17895776
Drug: Left-arm injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Left-arm injection of contrast material (80 mL, iodine concentration 300 mg/mL, 2 mL/s injection rate)
Trial: 11525314
Drug: Ro70-0004 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro70-0004 (5 mg)
Trial: 9350563
Drug: Triclosan-containing gel/dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclosan-containing gel/dentifrice combination
Trial: 9350563
Drug: Control gel/dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control gel/dentifrice combination
Trial: 1778859
Drug: Cefpirome 1
RxNorm normalized name: cefpirome 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 1 or 2 g bd for 5-9 days
Trial: 29288184
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (pressure bandages, (bed) rest and wound care)
Trial: 29288184
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (debridement, antibiotics and implant retention (DAIR))
Trial: 29288184
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment followed by DAIR if persistent leakage at day 16-17
Trial: 24792311
Drug: Bupivacaine block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine block (0.25%) injected into trocar incision sites, 10 mL for incisions 8 mm or greater, 5 mL for incisions 5 mm or less.
Trial: 16166442
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m(2) every 3 weeks)
Trial: 8940729
Drug: Hematopoietic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematopoietic growth factors (HGF) such as G-CSF and GM-CSF
Trial: 1565246
Drug: EMG-assisted botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG-assisted botulinum toxin (BOTOX) injections, N = 28
Trial: 1565246
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BOTOX) injections without EMG assistance, N = 24
Trial: 3907967
Drug: Norethisterone oenanthate
RxNorm normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone oenanthate (NET OEN) 50 mg alone
Trial: 3907967
Drug: Norethisterone oenanthate
RxNorm normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 5 mg
Trial: 3907967
Drug: Norethisterone oenanthate
RxNorm normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 2.5 mg or estradiol cypionate (E2 Cyp.)
Trial: 31483461
Drug: Short-term Treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term Treatment for Internet and Computer Game Addiction
Trial: 30152068
Drug: Intravaginal progesterone‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal progesterone‐releasing device (IVD) containing 0.78 g progesterone and saline (low P4 concentration)
Trial: 30152068
Drug: Intravaginal progesterone‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal progesterone‐releasing device (IVD) containing 1.56 g progesterone (high P4 concentration)
Trial: 22214276
Drug: BDP‐HFA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP‐HFA (100 μg twice daily)
Trial: 19581539
Drug: Temsirolimus 175
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly
Trial: 19581539
Drug: Temsirolimus 175
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 175 mg weekly for 3 weeks followed by 25 mg weekly
Trial: 15362749
Drug: Budesonide foam
RxNorm normalized name: budesonide Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide foam (2 mg/50 mL)
Trial: 15362749
Drug: Betamethasone enema
RxNorm normalized name: betamethasone Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone enema (5 mg/100 mL)
Trial: 11458140
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (same procedure without effective denervation)
Trial: 8420421
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ICI 204,219 orally
Trial: 3535695
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of 0.9% saline containing 1.5 mg PGE2
Trial: 3535695
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of 0.9% saline (placebo)
Trial: 21419317
Drug: Mixed-grain dietary
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-grain dietary product (MG)
Trial: 16517534
Drug: Piperacillin/tazobactam (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (80 mg/kg every 6 h, max 4.5 g/dose)
Trial: 16517534
Drug: Cefepime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (50 mg/kg every 8 h, max 2 g/dose)
Trial: 1601598
Drug: Home rehabilitation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home rehabilitation with planned physical therapy
Trial: 3547214
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol therapy
Trial: 3547214
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no betamimetic agents)
Trial: 27739087
Drug: Tonic infusion
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonic infusion of hypertonic saline into the right anterior temporalis muscle
Trial: 25721866
Drug: OM‐89S (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM‐89S (6 mg daily for 10 days, placebo for 20 days)
Trial: 25721866
Drug: Nitrofurantoin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (50 mg daily for 30 days)
Trial: 23889885
Drug: Traumeel ointment
RxNorm normalized name: Traumeel Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traumeel ointment (T-O)
Trial: 23889885
Drug: Traumeel gel
RxNorm normalized name: TRAUMEEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traumeel gel (T-G)
Trial: 23889885
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel (D-G)
Trial: 23889885
Drug: Traumeel ointment
RxNorm normalized name: Traumeel Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traumeel ointment (T-O) and Traumeel gel (T-G)
Trial: 20234828
Drug: Atomoxetine 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 2.4 mg/kg/day
Trial: 11421997
Drug: Lamotrigine 100
RxNorm normalized name: lamotrigine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 100 mg single dose
Trial: 11421997
Drug: Lamotrigine 100
RxNorm normalized name: lamotrigine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade B)
Trial: 11421997
Drug: Lamotrigine 100
RxNorm normalized name: lamotrigine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade C)
Trial: 9014993
Drug: Dofetilide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (both doses)
Trial: 8344127
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg.kg‐1.day‐1 for 10 days, then 0.3 mg.kg‐1.day‐1 for 50 days)
Trial: 15811647
Drug: Evidence-based lecture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based lecture on the benefits of the polio vaccine
Trial: 10587936
Drug: Enhanced Abbreviated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Abbreviated treatment
Trial: 10587936
Drug: 12-month course
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month course of treatment (including at least 6 months in a therapeutic community followed by outpatient treatment)